Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications.

Paul BD, Snyder SH.

Front Mol Neurosci. 2019 Mar 19;12:68. doi: 10.3389/fnmol.2019.00068. eCollection 2019. Review.

2.

Transcriptional control of amino acid homeostasis is disrupted in Huntington's disease.

Sbodio JI, Snyder SH, Paul BD.

Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8843-8. doi: 10.1073/pnas.1608264113. Epub 2016 Jul 19.

3.

Cystathionine γ-lyase deficiency mediates neurodegeneration in Huntington's disease.

Paul BD, Sbodio JI, Xu R, Vandiver MS, Cha JY, Snowman AM, Snyder SH.

Nature. 2014 May 1;509(7498):96-100. doi: 10.1038/nature13136. Epub 2014 Mar 26.

4.

Mutant Huntingtin and Elusive Defects in Oxidative Metabolism and Mitochondrial Calcium Handling.

Brustovetsky N.

Mol Neurobiol. 2016 Jul;53(5):2944-2953. doi: 10.1007/s12035-015-9188-0. Epub 2015 May 5. Review.

5.

Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.

Zhou X, Li G, Kaplan A, Gaschler MM, Zhang X, Hou Z, Jiang M, Zott R, Cremers S, Stockwell BR, Duan W.

Hum Mol Genet. 2018 May 1;27(9):1545-1555. doi: 10.1093/hmg/ddy061.

PMID:
29462355
6.
7.

Mitochondrial dynamics and quality control in Huntington's disease.

Guedes-Dias P, Pinho BR, Soares TR, de Proença J, Duchen MR, Oliveira JM.

Neurobiol Dis. 2016 Jun;90:51-7. doi: 10.1016/j.nbd.2015.09.008. Epub 2015 Sep 24. Review.

PMID:
26388396
8.

Huntington's Disease and Mitochondria.

Jodeiri Farshbaf M, Ghaedi K.

Neurotox Res. 2017 Oct;32(3):518-529. doi: 10.1007/s12640-017-9766-1. Epub 2017 Jun 21. Review.

PMID:
28639241
9.

PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).

Ratovitski T, Arbez N, Stewart JC, Chighladze E, Ross CA.

Cell Cycle. 2015;14(11):1716-29. doi: 10.1080/15384101.2015.1033595.

10.

Methylene Blue Partially Rescues Heart Defects in a Drosophila Model of Huntington's Disease.

Heidari R, Monnier V, Martin E, Tricoire H.

J Huntingtons Dis. 2015;4(2):173-86. doi: 10.3233/JHD-140130.

PMID:
26397898
11.

GLP-1 Analogue Liraglutide Attenuates Mutant Huntingtin-Induced Neurotoxicity by Restoration of Neuronal Insulin Signaling.

Chang CC, Lin TC, Ho HL, Kuo CY, Li HH, Korolenko TA, Chen WJ, Lai TJ, Ho YJ, Lin CL.

Int J Mol Sci. 2018 Aug 24;19(9). pii: E2505. doi: 10.3390/ijms19092505.

12.

Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.

Li X, Valencia A, Sapp E, Masso N, Alexander J, Reeves P, Kegel KB, Aronin N, Difiglia M.

J Neurosci. 2010 Mar 31;30(13):4552-61. doi: 10.1523/JNEUROSCI.5865-09.2010.

13.

Mitochondrial and metabolic-based protective strategies in Huntington's disease: the case of creatine and coenzyme Q.

Naia L, Ribeiro MJ, Rego AC.

Rev Neurosci. 2011 Dec 2;23(1):13-28. doi: 10.1515/RNS.2011.060. Review.

PMID:
22150069
14.

Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum.

Oliveira JM.

J Neurochem. 2010 Jul;114(1):1-12. doi: 10.1111/j.1471-4159.2010.06741.x. Epub 2010 Apr 9. Review.

15.

Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease.

Quintanilla RA, Johnson GV.

Brain Res Bull. 2009 Oct 28;80(4-5):242-7. doi: 10.1016/j.brainresbull.2009.07.010. Epub 2009 Jul 19. Review.

16.

Altered Expression of Matrix Metalloproteinases and Their Endogenous Inhibitors in a Human Isogenic Stem Cell Model of Huntington's Disease.

Naphade S, Embusch A, Madushani KL, Ring KL, Ellerby LM.

Front Neurosci. 2018 Feb 5;11:736. doi: 10.3389/fnins.2017.00736. eCollection 2017.

17.

Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin.

Jin YN, Yu YV, Gundemir S, Jo C, Cui M, Tieu K, Johnson GV.

PLoS One. 2013;8(3):e57932. doi: 10.1371/journal.pone.0057932. Epub 2013 Mar 1.

18.

Targeting ATM ameliorates mutant Huntingtin toxicity in cell and animal models of Huntington's disease.

Lu XH, Mattis VB, Wang N, Al-Ramahi I, van den Berg N, Fratantoni SA, Waldvogel H, Greiner E, Osmand A, Elzein K, Xiao J, Dijkstra S, de Pril R, Vinters HV, Faull R, Signer E, Kwak S, Marugan JJ, Botas J, Fischer DF, Svendsen CN, Munoz-Sanjuan I, Yang XW.

Sci Transl Med. 2014 Dec 24;6(268):268ra178. doi: 10.1126/scitranslmed.3010523.

PMID:
25540325
19.

Targeting the proteostasis network in Huntington's disease.

Soares TR, Reis SD, Pinho BR, Duchen MR, Oliveira JMA.

Ageing Res Rev. 2019 Jan;49:92-103. doi: 10.1016/j.arr.2018.11.006. Epub 2018 Nov 28. Review.

20.

Protective Effects of Antioxidants in Huntington's Disease: an Extensive Review.

Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T, Justin-Thenmozhi A, Ray B, Bhat A, Chidambaram SB, Fernandes AJ, Song BJ, Akbar M.

Neurotox Res. 2019 Apr;35(3):739-774. doi: 10.1007/s12640-018-9989-9. Epub 2019 Jan 11. Review.

PMID:
30632085

Supplemental Content

Support Center